Slide 1: 2021 Full Year Results and Business Updates
Abbisko Therapeutics 2021 FULL YEAR RESULTS AND BUSINESS UPDATES March 21, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements The accuracy of Abbisko’s estimates regarding expenses, future revenue, future expenditures and needs for and ability to obtain additional financing, Abbisko’s ability to obtain and maintain intellectual property protection for its product candidates and approved products,
Slide 3: Agenda
Agenda Opening Remarks Dr. Yao-Chang Xu Dr. Zhui Chen Business Update Dr. Jing Ji Financial Update Mr. Richard Yeh Closing Remarks Dr. Yao-Chang Xu Q&A 2
Slide 4: Opening Remarks
OPENING REMARKS 3
Slide 5: Discover and develop novel and differentiated therapies in oncology and beyond
DISCOVER AND DEVELOP NOVEL AND DIFFERENTIATED THERAPIES IN ONCOLOGY AND BEYOND, TO ADDRESS CRITICAL UNMET NEEDS FOR PATIENTS IN CHINA AND WORLDWIDE 3
Slide 6: 2021: A Year of Unprecedented Achievements and Growth
2021: A Year of Unprecedented Achievements and Growth KEY MILESTONES AND HIGHLIGHTS GLOBAL CLINICAL DEVELOPMENT EFFICIENT INTERNAL CAPABILITIES DISCOVERY ENGINE 6 Assets in clinical stage 10 PCCs discovered since 2017 10+ Clinical trials in four countries and regions ~2 PCCs delivered per year on av
Slide 7: Growing Business Scale with Expanded Footprint Globally
Growing Business Scale with Expanded Footprint Globally Clinical Development Manufacturing Clinical team presence in Shandong, One manufacturing plant in 10+clinical trials ongoing / Shaanxi, Heilongjiang, Hubei and Shanghai under planning Guangdong planned ABSK011 ABSK061 Clinical operations
Slide 8: Global Co-Discovery Collaboration with Eli Lilly and Company
Enhanced Business Development Exemplified by Global Co- Discovery Collaboration with Eli Lilly and Company INNOVATION GLOBOLIZATION A new collaboration model Potential financial benefits • Abbisko eligible to receive up to US$258m in • A worldwide co-discovery collaboration on a potential milestone
Slide 9: Well-Positioned To Thrive with Focus on Innovation and Globalization
Well-Positioned To Thrive with Focus on Innovation and Globalization Continuously deliver high-quality PCCs 1 Robust in-house discovery capability Sustain pipeline growth Ensure long-term success 2 Global clinical development capability Capture international market potential Extensive and growing pi
Slide 10: Business Update
BUSINESS UPDATE 9
Slide 11: Our Pipeline
Our Pipeline Assets Target Indication Mono/Combo Discovery IND Enabling Phase I/Ia POC (i) Pivotal Partner Rights Monotherapy ABSK011 FGFR4 FGF19+ HCC Global Combination therapy (ii) RMS and other ABSK012 FGFR4 mutant solid tumors Monotherapy Global Monotherapy Partner FGFRalt UC Precision Oncology
Slide 12: Multiple Global-Leading and Next-Generation Oncology Assets
Multiple Global-Leading and Next-Generation Oncology Assets ABSK011 Leading FGFR franchise with multiple next-gen FGFR inhibitors to address limitations of ABSK012 current pan-FGFR inhibitors ABSK091 Two generations of selective FGFR4 inhibitors for FGFR4 wild-type and mutations ABSK061 Selectiv
Slide 13: Clinical Achievements in 2021 (Part I)
Clinical Achievements in 2021 (Part I) Asset and trial Preclinical Phase I / Ia Phase Ib / II Completed Ph Ia Mono Before 2021 2021 Well into Ph Ib mono ABSK011 (HCC, China) FGFR4 Entered into collaboration with Roche Combo 2021 (Not applicable) * 2021 Well into Ph II combo (HCC, China) Co
Slide 14: Clinical Achievements in 2021 (Part II)
Clinical Achievements in 2021 (Part II) Asset and trial Preclinical Phase I / Ia Phase Ib / II A global Ph III trial in WHIM patients Ph III patient enrollment Mono conducted by X4 completed ABSK081 CXCR4 Well into Ph Ib / II Combo Before 2021 (Not application) * 2021 combo with Junshi PD-1 (TNB
Slide 15: Proprietary Discovery Engine with Global Quality and Efficiency
Proprietary Discovery Engine with Global Quality and Efficiency Fully integrated end-to-end High efficiency with global discovery engine quality and standard High efficiency in delivering ~2 PCCs Target identification Drug discovery Translational & per year & validation & optimization biomarker rese
Slide 16: Our Scientific Approach
Our Scientific Approach High potential next-generation small molecules Breakthrough innovation From 2016 From 2019 Now and near future Synthetic Precision Oncology Precision Oncology Lethality (FGFR franchise) (next-gen K-Ras, EGFR) Oncogenic Transcriptional Drivers Regulation Immuno-Oncology Immuno
Slide 17: Precision Oncology – FGFR Programs
Precision Oncology – FGFR Programs 16
Slide 18: FGFR1-4: Validated Pan-Cancer Targets with Large Market Potential
FGFR1-4: Validated Pan-Cancer Targets with Large Market Potential While Current FGFR-Agents Leave Significant Unmet Needs FGFR alterations are found in various cancers with Large therapeutic opportunities remain after 1st-gen ~1.9mn annual incidence globally4… inhibitors due to their toxicity, limit
Slide 19: High Unmet Medical Needs Remain in FGFR-Dependent Diseases
High Unmet Medical Needs Remain in FGFR-Dependent Diseases FGFR4 Selective Inhibitor FGFR2/3 Selective Inhibitor FGFR Resistant Mutations Large patient population in Current pan-FGFR inhibitors Acquired resistant mutations HCC and other cancer carry hyperphosphatemia in occurred upon treatment
Slide 20: Leading FGFR Franchise with Multiple Next-Generation FGFR Inhibitors
Leading FGFR Franchise with Multiple Next-Generation FGFR Inhibitors to Address Unmet Medical Needs for FGFR-Driven Patients Selectivity over FGFR1 to improve Overcome resistant Pan- safety and efficacy Selective mutations FGFR FGFR FGFR Mutant Inhibitor Inhibitor Inhibitor Indication coverage ABSK0
Slide 21: ABSK011 and ABSK012: Selective FGFR4 Inhibitors
ABSK011 and ABSK012: Selective FGFR4 Inhibitors for Wild-Type FGFR4 and Its Resistant Mutations Globally leading FGFR4 inhibitor with best-in- Excellent human PK with sufficient coverage of target class potential in phase Ib/II clinical trials for HCC Absk011 Plasma concentration on C1D15 ABSK011 pl
Slide 22: ABSK061 and ABSK121: Next-Generation FGFR Inhibitors
ABSK061 and ABSK121: Next-Generation FGFR Inhibitors to Improve Safety and Efficacy or Overcome Resistance Improved selectivity over FGFR1 compared to current pan-FGFR inhibitor Global leading, clinical stage FGFR2/3-selective inhibitor designed to reduce FGFR1-dependent Selectivity ratio over FGFR1
Slide 23: Precision Oncology – Two Recently Declared Next-Generation Candidates
Precision Oncology – Two Recently Declared Next-Generation Candidates 22
Slide 24: ABSK112: Next-Generation EGFR-Exon20ins Inhibitor
ABSK112: Next-Generation EGFR-Exon20ins Inhibitor with Improved Selectivity over Wild-Type and Strong Brain Penetrating Ability Current EGFR-exon20ins inhibitors face ABSK112 has excellent selectivity, broad spectrum mutation significant challenges in efficacy and safety coverage, and brain penetrat
Slide 25: ABSK071: Next-Generation KRAS G12C Inhibitor
ABSK071: Next-Generation KRASG12C Inhibitor with Increased On- Target Potency and Activity in Models Insensitive to Current Inhibitors Room to further improve efficacy of current ABSK071, a next-gen KRASG12C inhibitor demonstrating KRASG12C inhibitors through optimized potency, superior efficacy and
Slide 26: Immuno-Oncology
Immuno-Oncology Abbisko =
Slide 27: Immuno-Oncology Small Molecule Franchise
Immuno-Oncology Small Molecule Franchise Comprehensive coverage of broad tumor immune mechanisms ABSK021 – small molecule CSF-1R inhibitor Broad indications (macrophage-dependent diseases) Targeting a broad range of cancer In Ph Ib dose expansion study in mainland China and the U.S. immune cells
Slide 28: ABSK043: Oral PD-L1 Small Molecule Inhibitor
ABSK043: Oral PD-L1 Small Molecule Inhibitor with Strong Potency, Improved Safety and Broad Combination Potential Oral PD-L1 small molecules potentially offer unique ABSK043, a clinical stage oral PD-L1 small molecule advantages over PD-(L)1 mAbs inhibitor with excellent preclinical profile Enhanc
Slide 29: ABSK021: A Clinically Validated Target Linked to Many Diseases
ABSK021: A Clinically Validated Target Linked to Many Diseases with High Unmet Needs and Market Potential Neuro-degenerative Oncology Other TAs CSF-1R plays critical roles in various macrophage-dependent …and is a clinically diseases with significant unmet medical needs… validated target Clear and a
Slide 30: ABSK021: A Potential Best-In-Class CSF-1R Inhibitor
ABSK021: A Potential Best-In-Class, Clinical-Stage CSF-1R Inhibitor with Superior Activity, Selectivity, and Brain Penetrating Abilities Current CSF-1R inhibitors face significant ABSK021’s improved selectivity, potency, and CNS penetrating challenges in efficacy and safety abilities lead to better
Slide 31: Potential for Disease Areas Beyond Oncology
Potential for Disease Areas Beyond Oncology 30
Slide 32: Great Potential Beyond Oncology
Great Potential Beyond Oncology ACH ABSK061 ABSK043 HBV (hepatitis B (achondroplasia) FGFR2/3 PD-L1 virus) ALS (amyotrophic lateral sclerosis) WHIM (warts, cGvHD (chronic ABSK021 ABSK081 hypogammaglobuli graft-versus-host CSF-1R CXCR4 nemia, infections disease) and myelokathexis) IPF (idiopathic pul
Slide 33: Business Development
Business Development Abbisko
Slide 34: Out-licensing Agreement with Sperogenix for ABSK021
Out-licensing Agreement with Sperogenix for ABSK021 in Non- Oncology Neurological Indications Total ALS Patient Numbers (k) China ~60 • ABSK021, a CSF-1R inhibitor developed by Assets US ~20 Abbisko in-house RoW ~220 • Mainland China, Hong Kong SAR and Macao Region 冰桶挑战 SAR • ALS is a motor neuron d
Slide 35: Broad Collaborations with Leading Pharmaceutical Partners
Broad Collaborations with Leading Pharmaceutical Partners Global rights in- China rights in- Product In-licensing licensing of ABSK091 licensing of ABSK081 Out-licensing of ABSK021 China rights in non- oncology rare neurological diseases including Product Out-licensing ALS, with upfront payment and
Slide 36: Financial Update
FINANCIAL UPDATE Abbish * ko 3
Slide 37: Robust Financial Position to Support Future Business Growth
Robust Financial Position to Support Future Business Growth ~US$400m cash and cash equivalents to fund business activities Strong cash position with no near-term fund-raising pressure • Cash burn related to business operation of ~US$37m (i) in 2021 Disciplined financial • Committed to operational ef
Slide 38: Closing Remarks and 2022 Outlook
CLOSING REMARKS AND 2022 OUTLOOK 37
Slide 39: 2022: First Wave of Clinical Proof-of-Concept Data on the Horizon
2022: First Wave of Clinical Proof-of-Concept Data on the Horizon Pipeline Target Clinical trial Stage Event 1H 2022 2H 2022 1H 2023 Clinical candidates 2L HCC, mono Phase Ib Preliminary POC readout ABSK011 FGFR4 1L/2L HCC, combo Phase II Preliminary data readout 2L UC, mono Phase II Preliminary P
Slide 40: Thank You
Thank You Abbisko